NEOLEUKIN THERAPEUTICS INC (NLTX) Fundamental Analysis & Valuation

NASDAQ:NLTX • US64049K2033

Current stock price

3.49 USD
+0.05 (+1.45%)
At close:
3.42 USD
-0.07 (-2.01%)
After Hours:

This NLTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NLTX Profitability Analysis

1.1 Basic Checks

  • NLTX had negative earnings in the past year.
  • NLTX had a negative operating cash flow in the past year.
NLTX Yearly Net Income VS EBIT VS OCF VS FCFNLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -38.25%, NLTX is doing good in the industry, outperforming 63.11% of the companies in the same industry.
  • NLTX has a Return On Equity of -45.57%. This is in the better half of the industry: NLTX outperforms 69.12% of its industry peers.
Industry RankSector Rank
ROA -38.25%
ROE -45.57%
ROIC N/A
ROA(3y)-34.21%
ROA(5y)-38.12%
ROE(3y)-40.31%
ROE(5y)-42.67%
ROIC(3y)N/A
ROIC(5y)N/A
NLTX Yearly ROA, ROE, ROICNLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NLTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLTX Yearly Profit, Operating, Gross MarginsNLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NLTX Health Analysis

2.1 Basic Checks

  • NLTX has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, NLTX has a worse debt to assets ratio.
NLTX Yearly Shares OutstandingNLTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M
NLTX Yearly Total Debt VS Total AssetsNLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -6.37, we must say that NLTX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -6.37, NLTX is doing worse than 71.29% of the companies in the same industry.
  • NLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.37
ROIC/WACCN/A
WACCN/A
NLTX Yearly LT Debt VS Equity VS FCFNLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 15.37 indicates that NLTX has no problem at all paying its short term obligations.
  • NLTX's Current ratio of 15.37 is amongst the best of the industry. NLTX outperforms 89.32% of its industry peers.
  • NLTX has a Quick Ratio of 15.37. This indicates that NLTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 15.37, NLTX belongs to the top of the industry, outperforming 89.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.37
Quick Ratio 15.37
NLTX Yearly Current Assets VS Current LiabilitesNLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NLTX Growth Analysis

3.1 Past

  • NLTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.78%.
EPS 1Y (TTM)-136.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NLTX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.36% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.72%
EPS Next 2Y40.24%
EPS Next 3Y23.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLTX Yearly Revenue VS EstimatesNLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2027 2028 2029 2030 200M 400M 600M 800M
NLTX Yearly EPS VS EstimatesNLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. NLTX Valuation Analysis

4.1 Price/Earnings Ratio

  • NLTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NLTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLTX Price Earnings VS Forward Price EarningsNLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLTX Per share dataNLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • NLTX's earnings are expected to grow with 23.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.24%
EPS Next 3Y23.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NLTX Dividend Analysis

5.1 Amount

  • NLTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NLTX Fundamentals: All Metrics, Ratios and Statistics

NEOLEUKIN THERAPEUTICS INC

NASDAQ:NLTX (12/18/2023, 8:15:14 PM)

After market: 3.42 -0.07 (-2.01%)

3.49

+0.05 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-18
Inst Owners0.15%
Inst Owner Change0%
Ins Owners41.27%
Ins Owner Change0%
Market Cap30.71M
Revenue(TTM)N/A
Net Income(TTM)-34.27M
Analysts43.33
Price Target1.53 (-56.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-5.2
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-3.74
FCFYN/A
OCF(TTM)-3.67
OCFYN/A
SpS0
BVpS8.55
TBVpS8.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -38.25%
ROE -45.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.21%
ROA(5y)-38.12%
ROE(3y)-40.31%
ROE(5y)-42.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.37
Quick Ratio 15.37
Altman-Z -6.37
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.83%
EPS Next Y93.72%
EPS Next 2Y40.24%
EPS Next 3Y23.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.63%
OCF growth 3YN/A
OCF growth 5YN/A

NEOLEUKIN THERAPEUTICS INC / NLTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NEOLEUKIN THERAPEUTICS INC (NLTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NLTX.


Can you provide the valuation status for NEOLEUKIN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to NEOLEUKIN THERAPEUTICS INC (NLTX). This can be considered as Overvalued.


What is the profitability of NLTX stock?

NEOLEUKIN THERAPEUTICS INC (NLTX) has a profitability rating of 1 / 10.